BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 6, 2025
Home » Blogs » BioWorld MedTech Perspectives » Three stories for August 2012

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / NIH

Three stories for August 2012

Aug. 31, 2012
By Mark McCarty

Sometimes news comes in bunches. That’s not typically the case in the month of August, which is ordinarily a pretty quiet month. Not this year, though. Here are three stories that stick out, in one case like a sore thumb.

Post-market studies for ICD leads

FDA announced it will require section 522 studies for a range of ICD leads made by St. Jude Medical. This is not the first time the new FDA has required 522 studies for groups of devices as the 522 orders for surgical meshes, hip implants, and dynamic spinal stabilization systems suggest. I might add that companies whose wares have not presented statistically significant problems have been forced into the 522 march.

The lesson here is that a post-market 522 study is now the quasi-official FDA response to device problems that are not already tracked in a very extensive registry, and industry knows it. What will industry think about investing in the U.S. in the years ahead once they have to factor the cost of these studies into the product life cycle?

Hauser’s paper on abrasions: a correlation with extrusion?

Robert Hauser, MD, recently published in Europace on the matter of abrasions to St. Jude leads coated with the Optim co-polymer material. It’s another piece of news that could spell danger for patients and for the company … or not.

One thing Hauser’s piece did not explain was whether a correlation exists between abrasion from external sources and externalization of conductors. Maybe there aren’t a lot of data on this. I can’t seem to locate anything on this for ICD leads in general, let alone anything specific to the Optim coating. Will it turn out that the correlation between abrasion and externalization is puny?

One of the difficulties behind this discussion is that there are a lot more patients around who have had an ICD for some years than there were in times gone by. Consequently, electrophysiologists are cramming these skinnier leads into some spaces where there is already a lead that has gone kaput. Ergo, a higher rate of abrasions and externalizations might be partly or even principally due to the contortions a lead is exposed to in order to cram it into a tight anatomical space.

This is not a meaningless consideration. If there’s already a lead in there and you as a physician always resort to a skinny lead to replace a dead lead, the narrower lead already has a problem.

So before we wish skinny ICD leads out of existence by beating the daylights out of St. Jude, maybe we better find out if there is a correlation between abrasion and extrusion, and whether these leads are being used in ways that make it tough to avoid problems to begin with.

NEJM article on NIH spending

I mentioned at the outset that one of these three stories stuck out like a sore thumb. Here it is.

Those who have watched the MDD Perspectives blog for some time know how annoying I find the entire NIH funding discussion. Well, it’s still annoying.

I won’t carp about the cancer-versus-Alzheimer’s funding thing, but the authors of the paper on NIH spending in the Aug. 23 edition of the New England Journal of Medicine use advances in heart disease to justify more spending at NIH and the National Science Foundation. But really, doesn’t the medical device industry deserve most of the credit?

Another point raised in this and other arguments like it is that people with PhDs and MDs will find themselves unemployed. Well, there’s a lot of that going around lately and it’s no reason to throw taxpayer money at medical research. By that logic, anyone with a PhD in particle physics or a JD in constitutional law deserves to be employed via federal funding just by virtue of having a sheepskin. You never hear anyone sweating bullets over someone with a Bachelor’s degree in criminology, but if you have a PhD in a life science, well by golly, pull up your chair to the trough!

I dare someone who supports gobs of money for NIH to say “FDA needs it more. We’re okay with NIH funding where it is.” Why will that never happen? Because possession of a PhD does not blunt self-seeking behaviors even a tiny bit.

Funny how human nature never changes, isn’t it?

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 5, 2025.
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • Art concept for gene therapy

    Gene therapies aim for the big goal of edits in vivo

    BioWorld Science
    The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing